Jeffry Lawrence

Jeffry Lawrence

Company: SSI Strategy

Job title: VP, Medical

Seminars:

Designing an Appropriate Immunosuppressive Regimen to Minimize Impact of the Immune Response to Administered AAV Therapies 12:00 pm

This panel will be a structured conversation designed to answer key questions such as: Discuss the best methods to circumvent the activation of both innate and adaptive immune response to the protein capsid, vector genome and transgene product to ensure no SAEs to reduce risk of clinical holds Explore immunomodulating and suppressive regimens currently used…Read more

day: Day Two

Protocol Design of Early Stage AAV Clinical Trials for Safety Optimization 9:30 am

Uncover how AAV vectors (even within the same serotype) demonstrate significant diversity in the immune responses elicited and their clinical risk Explore how clinically significant adverse events have been observed with AAV vectors involving innate and adaptive immunity, specifically complement, leukocyte and cytokine activation, T cell responses, and humoral immunity Uncover all available information, including…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.